Foli Bio

Executive Summary

Foli Bio is a San Diego-based biotechnology company pioneering a non-invasive transcriptome platform, Foli-seq™, that analyzes human RNA from stool samples to provide a snapshot of gut mucosal biology. This innovative approach enables molecular insights for precision medicine and drug development, with initial applications in gastrointestinal diseases such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and colorectal cancer. Founded in 2021, Foli Bio addresses a critical need for non-invasive diagnostic tools that can capture real-time molecular changes in the gut, overcoming the limitations of traditional stool tests and invasive endoscopies. The company's technology holds promise for early disease detection, monitoring therapeutic response, and accelerating clinical trials through more precise patient stratification. By leveraging transcriptomic data, Foli Bio aims to transform the management of GI disorders, where current standard-of-care often relies on symptoms and indirect biomarkers.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major pharmaceutical company for IBD trial30% success
• Q4 2026Series A funding round to support clinical validation50% success
• Q1 2027Publication of proof-of-concept data in colorectal cancer screening40% success